美国医疗保健：制药业：健康政策小组会议记录：第46届年度全球医疗保健会议——关键要点

At our 46th Annual Global Healthcare Conference, we hosted a panel titled “The Outlook for Health Policy: Digesting Political and Regulatory Changes and Uncertainties” with a strategic consulting and policy development firm based out of Washington D.C. (link). The panel framed their perspectives on key healthcare issues, with a focus on most favored nation (MFN) drug pricing, the budget reconciliation process, potential for PBM and Medicare Advantage reform, changes within the HHS department, and pharma tariffs. Notably, the panelists sense that, after approximately six months from the EO (potentially in the fall after reconciliation), if the MFN discussions haven’t resulted in announcements made by manufacturers, there could be more specific directions to the agencies regarding implementation, which would likely be through the Center for Medicare and Medicaid Innovation (CMMI). We discuss key takeaways within. All views are those of the panel. Key Takeaways High level framing of heal